FDA clears tuberculosis drug for marketing.
D000904:Antibiotics, Antitubercular / Q000494:pharmacology* / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D012293:Rifampin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000904:Antibiotics, Antitubercular; D012293:Rifampin; C018421:rifapentine